| Literature DB >> 31081440 |
Emad Al-Yahya1,2, Maha T Mohammad1, Jennifer Muhaidat1, Saddam Al Demour3, Dania Qutishat1, Lara Al-Khlaifat1, Rasha Okasheh1, Sophie Lawrie2, Patrick Esser2, Helen Dawes2,4.
Abstract
The purpose of this cross-sectional study was to compare gait characteristics and functional balance Babilities in men with LUTS secondary to benign prostatic hyperplasia (BPH) to those of community-dwelling older adults under different conditions of increasing difficulties, and to aid health-care providers to identify those patients with decreased level of activity and increased risk of falls. We recruited a group of 43 men diagnosed with symptomatic BPH and a control group of 38 older men. Participants performed the timed up and go and 10-m walking tests under different conditions-namely, single task, dual-task motor, and dual-task cognitive. Time to complete the tests and spatial and temporal gait parameters were compared between groups and conditions via mixed-design ANOVA. Under dual-task conditions, individuals in both groups performed significantly worse compared to the single functional balance and walking tasks. As the complexity of the walking task increased-from dual-task motor to dual-task cognitive-significant differences between groups emerged. In particular, men with BPH performed worse than older adults in tasks demanding increased attentional control. Results suggest that dual-task decrements in functional balance and gait might explain decreased level of physical activity and increased risk of falls reported in men with LUTS. Health-care providers for men with LUTS due to BPH should assess for abnormal gait and remain vigilant for balance problems that may lead to decreased mobility and falls. The dual-task approach seems a feasible method to distinguish gait and balance impairments in men with BPH.Entities:
Keywords: BPH; LUTS; dual task; gait; older adults; physical activity
Year: 2019 PMID: 31081440 PMCID: PMC6537265 DOI: 10.1177/1557988319839879
Source DB: PubMed Journal: Am J Mens Health ISSN: 1557-9883
Participants’ Demographics.
| BPH/LUTS | Older adults | Independent sample | ||
|---|---|---|---|---|
|
| Sig. (2-tailed) | |||
| Age | 64.6 ± 11.5 | 69.7 ± 6.1 | 2.540 | . |
| Height (m) | 1.71 ± 0.07 | 1.71 ± 0.06 | 0.018 | .986 |
| Weight (kg) | 84.3 ± 13.2 | 83.5 ± 11.1 | −0.295 | .768 |
| Number of medications | 4.14 ± 2.59 | 2.39 ± 2.15 | −3.275 | . |
| MMSE | 27.5 ± 2.4 | 27.7 ± 1.9 | −0.373 | .710 |
| SF-36 | ||||
| Physical functioning | 76.3 ± 20.5 | 78.7 ± 14.7 | −0.612 | .550 |
| Role functioning/physical | 20.3 ± 34.2 | 73.7 ± 38.1 | −6.598 |
|
| Role functioning/emotional | 28.7 ± 42.2 | 92.1 ± 21.1 | −8.706 |
|
| Energy/fatigue | 59.3 ± 18.7 | 74.6 ± 14.9 | −4.083 |
|
| Emotional well-being | 71.0 ± 18.3 | 84.8 ± 13.5 | −3.866 |
|
| Social functioning | 82.6 ± 21.2 | 89.5 ± 16.6 | −1.647 | .104 |
| Pain | 76.9 ± 22.6 | 77.4 ± 24.5 | −0.098 | .922 |
| General health | 60.1 ± 16.5 | 64.3 ± 19.7 | −1.048 | .298 |
| Health change | 56.4 ± 22.6 | 51.9 ± 21.3 | 0.908 | .367 |
Note. BPH = benign prostatic hyperplasia; LUTS = lower urinary tract symptoms; MMSE = Mini-Mental State Examination. Significant p values at a prior .05 alpha are in bold.
Patients With LUTS Details.
| LUTS onset in months,[ | 18.9 ± 12.2 |
| IPSS questionnaire | |
| Mean ± | 22 ± 6 |
| Median (Min–Max) | 21 (8–33) |
| Moderate symptoms, | 14 (32.5) |
| Severe symptoms, | 29 (67.5) |
| LUTS/BPH medications | |
| Alpha-blockers, | 43 (100) |
| 5-Alpha reductase inhibitors, | 14 (32.5) |
| Anticholinergics, | 6 (14) |
| Urodynamics and ultrasonography | |
| Pre-void volume (ml), mean ± | 385 ± 152 (109–650) |
| Post void residual (ml), mean ± | 105 ± 69 (0–265) |
| Q-Max (ml/s), mean ± | 14 ± 4 (8–34) |
| Prostate size (ml), mean ± | 56 ± 14 (26–80) |
Note. BPH = benign prostatic hyperplasia; LUTS = lower urinary tract symptoms; IPSS = International Prostate Symptom Score.
Based on their initial visit to JUH urology clinic.
Functional Balance (TUG) and Gait Time (10 m).
| BPH/LUTS ( | Older rdults ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ST | DT-motor | DT-cognitive | ST | DT-motor | DT-cognitive | Task | Group | Interaction | |
| TUG (second) | 12.1 ± 2.7 | 12.7 ± 3 | 15.3 ± 4.3 | 11.1 ± 2.7 | 13.5 ± 3.7 | 14.4 ± 4 | .509 | .684 | . |
| 10 m (second) | 9.8 ± 1.9 | 9.9 ± 2.3 | 13.2 ± 4.2 | 9.7 ± 2.1 | 10.3 ± 2.4 | 11.2 ± 2.6 | .341 | .476 | . |
Note. TUG = Timed Up and Go; BPH = benign prostatic hyperplasia; LUTS = lower urinary tract symptoms; ANOVA = analysis of variance; ST = single task; DT = dual task. Significant p values at a prior .05 alpha are in bold.
Spatial and Temporal Parameters of Gait.
| BPH/LUTS ( | Older adults ( | ||||||||
|---|---|---|---|---|---|---|---|---|---|
| ST | DT-motor | DT-cognitive | ST | DT-motor | DT-cognitive | Task | Group | Interaction | |
| Step time (ms) | 591 ± 66 | 590 ± 70 | 677 ± 118 | 559 ± 47 | 564 ± 62 | 637 ± 82 | . | .156 | .779 |
| Step time variability | 26.2 ± 13.6 | 34.0 ± 17.1 | 40.2 ± 28.4 | 40.6 ± 32.2 | 44.3 ± 39.8 | 56.6 ± 36.7 | .382 | .092 | .709 |
| Stride length (m) | 1.41 ± 0.12 | 1.37 ± 0.11 | 1.32 ± 0.11 | 1.43 ± 0.12 | 1.36 ± 0.11 | 1.39 ± 0.11 | . | .425 |
|
| Stride length variability (cm) | 3.1 ± 1.0 | 2.3 ± 2.2 | 3.8 ± 1.6 | 7.1 ± 4.4 | 9.7 ± 5.3 | 8.5 ± 4.5 | .311 |
| . |
| Cadence (step/min) | 99.1 ± 11.1 | 102.4 ± 11.8 | 90.3 ± 15.4 | 117.0 ± 26.1 | 114.8 ± 33.8 | 104.4 ± 24.3 | .218 | . | .609 |
| Cadence variability | 1.1 ± 2.7 | 4.8 ± 4.3 | 1.6 ± 3.3 | 21.1 ± 35 | 21.3 ± 54.8 | 23.9 ± 38 | .833 | . | .581 |
Note. BPH = benign prostatic hyperplasia; LUTS = lower urinary tract symptoms; ANOVA = analysis of variance; ST = single task; DT = dual task. Significant p values at a prior .05 alpha are in bold.
Figure 1.Group means (and standard errors) of different gait parameters (a. step time, b. stride length, and c. cadence) measured while performing the 10-m walking test under different conditions. Asterisks denote significant differences between groups. Double asterisks denote significant differences between tasks.